Moo-Kang Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Moo-Kang Kim has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Choon-Soo Lee
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine or College of Pharmacy, Seoul National University, South Korea (M.K., C.-S.L., H.S., H.J.S., H.-S.K.).
1 shared publication Dong-Sun Kim
SoC Platform Research Center, Korea Electronics Technology Institute, Seongnam 463-816, Republic of Korea
1 shared publication- Eue-Keun Choi
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
1 shared publication - Hanjun Ryu
Department of Advanced Materials Engineering, Chung-Ang University, Anseong-si 17546, Gyeonggi-do, Republic of Korea
1 shared publication - Hong-Joon Yoon
Department of Semiconductor Engineering, Gachon University, Seongnam 13120, Republic of Korea
1 shared publication - Hyo-Soo Kim
Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
1 shared publication
Latest Publications
- 8 November 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (11) , 1098-1115
Latrophilin-2 Deletion in Cardiomyocyte Disrupts Cell Junction, Leading to D-CMP
BACKGROUND: Latrophilin-2 (Lphn2), an adhesive GPCR (G protein-coupled receptor), was found to be a specific marker of cardiac progenitors during the differentiation of pluripotent stem cells into cardiomyocytes or during embryonic heart development in our previous studies. Its role in adult heart physiology, however, remains unclear. METHODS: The embryonic lethality resulting from Lphn2 deletion necessitates the establishment of cardiomyocyte-specific, tamoxifen-inducible Lphn2 knockout mice, which was achieved by crossing Lphn2 flox/flox mice with mice having MerCreMer (tamoxifen-inducible Cre [Cyclization recombinase] recombinase) under the α-myosin heavy chain promoter. RESULTS: Tamoxifen treatment for several days completely suppressed Lphn2 expression, specifically in the myocardium, and induced the dilated cardiomyopathy (D-CMP) phenotype with serious arrhythmia and sudden death in a short period of time. Transmission electron microscopy showed mitochondrial abnormalities, blurred Z-discs, and dehiscent myofibrils. The D-CMP phenotype, or heart failure, worsened during myocardial infarction. In a mechanistic study of D-CMP, Lphn2 knockout suppressed PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) and mitochondrial dysfunction, leading to the accumulation of reactive oxygen species and the global suppression of junctional molecules, such as N-cadherin (adherens junction), DSC-2 (desmocollin-2; desmosome), and connexin-43 (gap junction), leading to the dehiscence of cardiac myofibers and serious arrhythmia. In an experimental therapeutic trial, activators of p38-MAPK (p38 mitogen-activated protein kinases), which is a downstream signaling molecule of Lphn2, remarkably rescued the D-CMP phenotype of Lphn2 knockout in the heart by restoring PGC-1α and mitochondrial function and recovering global junctional proteins. CONCLUSIONS: Lphn2 is a critical regulator of heart integrity by controlling mitochondrial functions and cell-to-cell junctions in cardiomyocytes. Its deficiency leads to D-CMP, which can be rescued by activators of the p38-MAPK pathway.
- 8 November 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (11) , 1098-1115
Latrophilin-2 Deletion in Cardiomyocyte Disrupts Cell Junction, Leading to D-CMP
BACKGROUND: Latrophilin-2 (Lphn2), an adhesive GPCR (G protein-coupled receptor), was found to be a specific marker of cardiac progenitors during the differentiation of pluripotent stem cells into cardiomyocytes or during embryonic heart development in our previous studies. Its role in adult heart physiology, however, remains unclear. METHODS: The embryonic lethality resulting from Lphn2 deletion necessitates the establishment of cardiomyocyte-specific, tamoxifen-inducible Lphn2 knockout mice, which was achieved by crossing Lphn2 flox/flox mice with mice having MerCreMer (tamoxifen-inducible Cre [Cyclization recombinase] recombinase) under the α-myosin heavy chain promoter. RESULTS: Tamoxifen treatment for several days completely suppressed Lphn2 expression, specifically in the myocardium, and induced the dilated cardiomyopathy (D-CMP) phenotype with serious arrhythmia and sudden death in a short period of time. Transmission electron microscopy showed mitochondrial abnormalities, blurred Z-discs, and dehiscent myofibrils. The D-CMP phenotype, or heart failure, worsened during myocardial infarction. In a mechanistic study of D-CMP, Lphn2 knockout suppressed PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) and mitochondrial dysfunction, leading to the accumulation of reactive oxygen species and the global suppression of junctional molecules, such as N-cadherin (adherens junction), DSC-2 (desmocollin-2; desmosome), and connexin-43 (gap junction), leading to the dehiscence of cardiac myofibers and serious arrhythmia. In an experimental therapeutic trial, activators of p38-MAPK (p38 mitogen-activated protein kinases), which is a downstream signaling molecule of Lphn2, remarkably rescued the D-CMP phenotype of Lphn2 knockout in the heart by restoring PGC-1α and mitochondrial function and recovering global junctional proteins. CONCLUSIONS: Lphn2 is a critical regulator of heart integrity by controlling mitochondrial functions and cell-to-cell junctions in cardiomyocytes. Its deficiency leads to D-CMP, which can be rescued by activators of the p38-MAPK pathway.
- Top Cited Papers
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 365 (6452) , 491-494
Transcutaneous ultrasound energy harvesting using capacitive triboelectric technology
A sound way to deliver power: Implanted medical devices, such as pacemakers and neurological stimulators, require a source of power, usually in the form of a battery. If a battery is implanted with the device, replacing it would require additional surgery. On the other hand, external power packs are prone to lead to infections where their wires enter the body. Hinchet et al. describe a triboelectric generator that can convert externally applied ultrasound into an internal electricity source capable of delivering sufficient energy to recharge a battery on a daily basis. Science , this issue p. 491
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 365 (6452) , 491-494
Top Cited PapersTranscutaneous ultrasound energy harvesting using capacitive triboelectric technology
A sound way to deliver power: Implanted medical devices, such as pacemakers and neurological stimulators, require a source of power, usually in the form of a battery. If a battery is implanted with the device, replacing it would require additional surgery. On the other hand, external power packs are prone to lead to infections where their wires enter the body. Hinchet et al. describe a triboelectric generator that can convert externally applied ultrasound into an internal electricity source capable of delivering sufficient energy to recharge a battery on a daily basis. Science , this issue p. 491